Minimally interventional study on prevalence of emerging ESR1 mutations in liquid biopsy in three cohorts of patients with breast cancer in comparison with patient's baseline ESR1 mutation status as defined by tissue profiling.

Trial Identifier: D3612L00003
Sponsor: AstraZeneca
Start Date: June 2024
Primary Completion Date: December 2027
Study Completion Date: December 2027
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Brazil, Bahia Salvador, Bahia, Brazil, 41.950-640
Brazil, Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil, 90020-090
Brazil, São Paulo São Paulo, Brazil, 04513-020
Brazil, São Paulo São Paulo, Brazil, 01.509-900
Brazil, São Paulo São Paulo, Brazil, 01401-002
Brazil, São Paulo São Paulo, Brazil, 05652-000